Breast Cancer

, Volume 13, Issue 3, pp 284–288 | Cite as

Joint symptoms: A practical problem of anastrozole

  • Tomofumi Ohsako
  • Katsuhiko Inoue
  • Norihide Nagamoto
  • Yasushi Yoshida
  • Osamu Nakahara
  • Namiko Sakamoto
Original Article



Anastrozole and tamoxifen have mild toxicity. However, we noticed that more patients treated with anastrozole complained of joint symptoms than expected. In particular, digital stiffness as is seen with rheumatoid arthritis is a problem. Some clinical trials of anastrozole in Europe and the United States reported musculoskeletal disorders as adverse events, however, joint symptoms were not described in detail.

Patients and Methods

At our clinic from August 2001 to March 2005, 53 postmenopausal women with estrogen receptor-positive breast cancer were treated with anastrozole. We calculated the incidence and classified the grade of joint symptoms by interviewing patients. We also investigated the patients’ characteristics and their relevance to joint symptoms.


Of 53 patients, 14 patients (26%) had joint symptoms (13 patients with digital stiffness and 3 patients with arthralgias of wrist and shoulders). Joint symptoms tended to occur in the patients who had previously undergone chemotherapy; however, there has no relationship between prior hormonal therapy and joint symptoms. Seven patients who discontinued anastrozole treatment showed improved symptoms. Five patients with grade 1 digital stiffness continued anastrozole treatment without additional treatment. Two patients with grade 1 digital stiffness, who took a Chinese herbal medicine showed improved symptoms and continued anastrozole treatment.


Benefits to the patients may possibly be lost by discontinuation of anastrozole or changing to tamoxifen since the clinical superiority of anastrozole to tamoxifen has been reported. We should continue anastrozole in patients with low grade symptoms, while ensuring that patients are aware of the toxicity of anastrozole.

Key words

Joint symptom Digital stiffness Anastrozole Breast cancer 



Common terminology criteria for adverse events version 3.0


Matrix metalloproteinase 3


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1).
    Buzdar AU, Jones SE, Vogel CL, Wolter J, Plourde P, Webster A. A phase HI trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma.Cancer 79:730–739, 1997.PubMedCrossRefGoogle Scholar
  2. 2).
    Jonat W, Howell A, Blomqvist C, Eiermann W, Winblad G, Tyrrell C, Mauriac L, Roche H, Lundgren S, Hellmund R, Azab M: A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer.Eur J Cancer 32:A404–412, 1996.CrossRefGoogle Scholar
  3. 3).
    Buzdar AU, Jonat W, Howell A, Jones SE, Blomqvist CP, Vogel CL, Eiermann W, Wolter JM, Steinberg M, Webster A, Lee D: Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase HI trials. Arimidex Study Group.Cancer 83:1142–1152, 1998.PubMedCrossRefGoogle Scholar
  4. 4).
    Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A Sahmoud T: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.Cancer 98:1802–1810, 2003.PubMedCrossRefGoogle Scholar
  5. 5).
    Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer.Lancet 365:60–62, 2005.PubMedCrossRefGoogle Scholar
  6. 6).
    Winer EP, Hudis C, Burstein HJ, Chlebowski RT, Ingle JN, Edge SB, Mamounas EP, Gralow J, Goldstein LJ, Pritchard KI, Braun S, Cobleigh MA, Langer AS, Perotti J, Powles TJ, Whelan TJ, Browman GP: American society of clinical oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002.J Clin Oncol 20:3317–3327, 2002.PubMedCrossRefGoogle Scholar
  7. 7).
    The NCI Common Terminology Criteria for Adverse Events version 3.0:2003.Google Scholar
  8. 8).
    Tanizaki K, Takatani H, Mifune H,et al: Clinical effectiveness of Tsumura Keishika-jupputo for rheumatoid arthritis.Rinnsho To Kennkyu 70:2285–2292 (in Japanese).Google Scholar
  9. 9).
    Donnellan PP: Aromatase Inhibitors and Arthralgia.J Clin Oncol 19:2767, 2001.PubMedGoogle Scholar
  10. 10).
    Dombernowsky P, Smith I, Folkson G,et al: Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing dose effect and improved efficacy and tolerability compared with megestrol acetate.J Clin Oncol 16:453–461, 1998.PubMedGoogle Scholar
  11. 11).
    Goss PE, Winer EP, Tannock IF,et al: Randomized phase HI trial comparing the new potent and selective third generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients: North American Vorozole Study Group.J Clin Oncol 17:52–63, 1999.PubMedGoogle Scholar
  12. 12).
    Jones S, Vogel C, Arckhipov A, Fehrenbacher L, Eisenbeg P, Cooper B, Honig S, Polli A, Whaley F, di Salle E, Tiffany J, Consonni A, Miller L for the Aromasin Study Group: Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer.J Clin Oncol 17:3418–3425, 1999.PubMedGoogle Scholar
  13. 13).
    Pansini F, Albertazzi P, Bonaccorsi G,et al: The menopausal transition: A dynamic approach to the pathogenesis of neurovagetative complaints.Eur J Obstet Gynecol Reprod Biol 57:103–109, 1994.PubMedCrossRefGoogle Scholar
  14. 14).
    Yamanaka H, Matsuda Y, Tanaka M,et al: Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement in patients with early rheumatoid arthritis.Arthritis Rheum 43:852–858, 2000.PubMedCrossRefGoogle Scholar
  15. 15).
    Christgau S, Garnero P, Fledelius C, Moniz C, Ensig M, Gyneyts E, Rosenquist C, Qvist P: Collagen type II C-telopeptide fragments as an index of cartilage degradation.Bone 29:209–215, 2001.PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Breast Cancer Society 2006

Authors and Affiliations

  • Tomofumi Ohsako
    • 1
  • Katsuhiko Inoue
    • 1
  • Norihide Nagamoto
    • 1
  • Yasushi Yoshida
    • 1
  • Osamu Nakahara
    • 1
  • Namiko Sakamoto
    • 1
  1. 1.Department of SurgeryJapan Labour Health and Welfare Organization Kumamoto Rosai HospitalJapan

Personalised recommendations